Alkermes plc ( ALKS) - Key Metrics
ALKS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q1 | ? | ? | ? | ? |
| 2025Q4 | $2.33 | $0.30 | -$2.13 | -$1.88 |
| 2025Q3 | $2.39 | $0.50 | $0.62 | $0.51 |
| 2025Q2 | $2.37 | $0.53 | $0.91 | $0.83 |
| 2025Q1 | $1.88 | $0.14 | $0.60 | $0.54 |
ALKS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q1 | ? | ? |
| 2025Q4 | ? | 23.35 |
| 2025Q3 | ? | 14.96 |
| 2025Q2 | ? | 13.55 |
| 2025Q1 | ? | 60.05 |
ALKS Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q1 | -2.89% | ? |
| 2025Q4 | 3.69% | ? |
| 2025Q3 | 1.70% | ? |
| 2025Q2 | 2.91% | ? |
| 2025Q1 | 1.64% | ? |
ALKS
Price: $42.78
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.90 USD
P/E Ratio: 39.41
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Ireland
Volume: 283127
Ebitda: 39.2 millionMarket Capitalization: 7.2 billion